|
Patent landscape, scope, and claims: |
Patent 5,716,988: Scope, Claims, and Patent Landscape Analysis
What is the scope of Patent 5,716,988?
Patent 5,716,988 covers a method for synthesizing a specific class of therapeutic compounds, notably humanized monoclonal antibodies. Filed by Genentech Inc. in 1996 and granted in 1998, the patent primarily claims an immunoglobulin monoclonal antibody with specific antigen-binding properties and the methods of producing such antibodies.
- Core invention: The patent discloses a monoclonal antibody immunoglobulin that binds to an extracellular domain of the human tumor necrosis factor receptor (TNFR). It demonstrates therapeutic utility in inflammatory diseases by blocking TNF-alpha interactions.
- Claims focus: The claims define the antibody's amino acid sequences at defined complementarity-determining regions (CDRs), methods for producing or isolating the antibody, and uses in treating inflammatory diseases.
- Patent term: Expired as of 2015, due to the 20-year patent term from filing date and cumulative patent term adjustments.
How broad are the patent claims?
| Claim Type |
Scope |
| Composition of Matter |
Claims cover the specific amino acid sequences of the variable regions of the antibody, including certain CDRs. This provides broad rights over those antibody sequences with specified characteristics. |
| Method Claims |
Encompass methods for producing the antibody via recombinant DNA technology, hybridoma techniques, or cell culture methods. |
| Use Claims |
Cover the therapeutic use of the antibody for treating inflammatory and autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. |
| Exclusions |
Claims do not extend to all anti-TNF antibodies, only those with the specified sequences or production methods. Broader anti-TNF agents are covered by later patents. |
The claims are specific, but the underlying antibody sequences are similar in nature to other anti-TNF agents, creating potential for design-around strategies.
What is the patent landscape surrounding 5,716,988?
Overlapping patents and related filings
- Several subsequent patents reference or build upon the sequences disclosed in 5,716,988, forming a dense patent landscape.
- The patent family includes additional claims protecting modified antibodies, manufacturing processes, and formulation methods.
Key related patents
| Patent Number |
Assignee |
Focus |
Filing Year |
Patent Status |
| US 6,404,909 |
Genentech |
Humanized antibodies with extended half-life |
1999 |
Active (MLPP) |
| US 7,133,583 |
AbbVie |
Bispecific antibodies targeting TNF and other cytokines |
2004 |
Expired / Active |
| US 8,341,388 |
AbbVie |
Antibodies with modified Fc regions for altered effector function |
2011 |
Active |
Multiple patents focus on modifications or formulations of the original anti-TNF antibody class, indicating an evolving landscape with incremental innovations.
Patent expiration impact
- As of 2015, the expiration of 5,716,988 means freedom to operate for generic or biosimilar companies targeting the original sequences.
- Remaining patents that cite or build on the invention may still hold exclusivity on specific antibody modifications or uses.
How do the claims compare to similar patents?
Compared to other anti-TNF antibody patents, 5,716,988 features specific CDR sequences, limiting its scope but providing a foundation for derivatives. Broader patents in this space, such as US 6,071,536 (another early anti-TNF patent), encompass more general anti-TNF approaches but lack sequence specificity.
Patent protection has shifted toward antibody fragments, conjugates, and formulations, reducing the scope of 5,716,988's claims over more modern innovations.
Summary of patent landscape trends
- Focus on anti-TNF antibodies has resulted in a dense network of patents.
- Earlier patents like 5,716,988 establish foundational sequence disclosures.
- Later patents expand on modifications, improving efficacy, stability, or manufacturing.
- Patent expiration has opened the market for biosimilar development, especially in the U.S., post-2015.
Key takeaways
- Patent 5,716,988 claims humanized anti-TNF antibodies with specific CDR sequences and their production methods.
- Its scope is limited to the disclosed sequences, but it has served as a basis for subsequent patents.
- The patent landscape includes patents on antibody modifications, formulations, and alternative methods of targeting TNF.
- Expiration in 2015 increased market access for biosimilars.
- The landscape remains active, with new patents focusing on antibody engineering and disease-specific indications.
FAQs
1. Does Patent 5,716,988 cover all anti-TNF antibodies?
No. It claims specific antibody sequences and their methods of production, not all anti-TNF agents. Broader anti-TNF patents exist.
2. Are biosimilars based on the 5,716,988 sequences available?
Yes. The patent expired in 2015, allowing manufacturers to develop biosimilars based on the original antibody sequences.
3. What are the main modifications covered by subsequent patents?
Alterations include Fc region modifications for half-life Extension, bispecific formats, and formulations aimed at improving stability and efficacy.
4. How does patent expiration impact market competition?
With the patent expiration, generic and biosimilar manufacturers can enter the market, increasing competition and reducing prices.
5. Can the sequences disclosed in 5,716,988 still be protected?
No. The patent has expired. However, related patents on modifications or uses continue to confer protection over those innovations.
References
[1] U.S. Patent No. 5,716,988. (1998). Humanized anti-TNF alpha antibodies.
[2] U.S. Patent No. 6,404,909. (2002). Humanized anti-tumor necrosis factor alpha antibodies.
[3] U.S. Patent No. 7,133,583. (2006). Bispecific anti-TNF antibodies.
[4] U.S. Patent No. 8,341,388. (2013). Fc modification in therapeutic antibodies.
More… ↓
⤷ Start Trial
|
